Cite
HARVARD Citation
McInnes, I. et al. (n.d.). OP0222 Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 104 weeks results from a phase 3 trial, future 2. Annals of the rheumatic diseases. p. 145. [Online].